In Practice

New CDC-NTDS Online Learning Module: Managing Infection in an Outpatient Dialysis Facility

The Centers for Disease Control and Prevention (CDC) and Nephrologists Transforming Dialysis Safety (NTDS) have partnered to develop a fresh, new online learning module, Managing Infection in an Outpatient Dialysis Facility.

The module is available to all members of the nephrology care team, including physicians, nurses, fellows, technicians, patients, and kidney educators, via an open-access platform.

The Kidney Health Initiative Welcomes New FDA Commissioner

KHI_Logo-Horizontal-Color_1.jpgThe Kidney Health Initiative (KHI) sent a congratulatory letter to Stephen Hahn, MD, on his recent confirmation as Commissioner of the US Food and Drug Administration (FDA).

Designing Clinical Trials for Innovative RRT Products: A New KHI Project

KHI_Logo-Horizontal-Color_0.jpgThe Advancing American Kidney Health initiative made developing an artificial kidney a national priority. The increased interest, investment, and innovation brought about by this policy highlight the need for new and improved infrastructure to facilitate innovation.

Fourth Annual NephJC Kidneys Awards Announces Winner of New CJASN NephJC Kidney Award for Best Visual Abstract 2019

The fourth annual NephJC Kidneys awards were hosted in Washington, DC on Friday, November 8 to coincide with ASN Kidney Week 2019. NephJC is an online medical journal club. They utilize social media and, in particular, the Twitter community to generate discussion and review current literature related to nephrology. It is open to anyone: nephrologists, residents, fellows, cardiologists, internists, urologists, radiologists, pharmacologists, and patients contribute to the discussion. Many contributors attended the NephJC event and took part in the Tweet-up.

Biopsies the “Imperfect Gold Standard” for Diagnosing Post-Transplant Rejection

WASHINGTON, DC -- Biopsies remain the gold standard for diagnosing post-transplant kidney disease but they are imperfect, a speaker said here during Kidney Week 2019. Emerging biomarkers may provide a complement to helping nephrologists diagnose and manage disease. The session entitled, "Needle Phobia: Kidney Transplant Biopsy Alternatives", included four speakers on the topic.

Three research scientists, including a nephrologist, awarded Nobel Prize in Medicine for work with how cells sense and adapt to oxygen

Announced on October 7th, the Nobel Prize in Medicine was jointly awarded to a trio of scientists, William G. Kaelin Jr., Peter J. Ratcliffe, and Gregg L. Semenza, for their work on “how cells sense and adapt to oxygen availability,” The New York Times reports.

These “investigators uncovered detailed genetic responses to changing oxygen levels that allow cells in the bodies of humans and other animals sense and respond to fluctuations, increasing and decreasing how much oxygen they receive.”

KidneyX award recipient receives HHS contract to provide hemodialysis systems for disaster response

The U.S. Department of Health and Human Services (HHS) has awarded a contract to a KidneyX award winner to provide hemodialysis systems in communities hit by natural disasters. The HHS Office of the Assistant Secretary for Preparedness and Response has stated it will be prepared to use the systems by the end of this year.

JASN Editor in Chief Josie Briggs, MD, Appointed Interim Executive Director of PCORI

On September 27th, the Patient-Centered Outcomes Research Institute (PCORI) announced the appointment of Josephine P. Briggs, MD, as PCORI’s Interim Executive Director, starting on November 1, 2019. Briggs will lead the organization during its search for a replacement for Joe Selby, MD, MPH, who announced plans to retire as Executive Director by year’s end. She will continue her work as JASN Editor-in-Chief during this time.

FDA approves first new treatment in 20 years to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure

The U.S. FDA has now approved INVOKANA® (canagliflozin) as the only type 2 diabetes (T2D) medicine indicated to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.  Approximately 1 in 3 patients with T2D also has DKD, which can ultimately lead to kidney failure. Once patients reach kidney failure, the average 5-year survival is less than 40%, largely due to cardiovascular-associated morbidity and mortality.

Dr. Reshma Kewalramani named incoming president and CEO of Vertex Pharmaceuticals, former member ASN KHI Board of Directors

Announced July 25, Dr. Reshma Kewalramani will be promoted to president and CEO of Vertex Pharmaceuticals. She is currently the chief medical officer for the company and was previously a practicing nephrologist who earned her medical doctorate at Boston University and trained at Bigham & Women’s Hospital.

Dr. Kewalramani will be the first woman to run a large biotechnology firm. Vortex’s share price “rose 360% and its sales doubled to $3 billion annually” under the previous CEO, largely due the company’s pharmaceuticals used to treat cystic fibrosis.

Pages